Skip to main content
. 2016 Aug 11;18(10):1434–1441. doi: 10.1093/neuonc/now091

Fig. 2.

Fig. 2.

OS of patients who changed from having a nondiffuse tumor at baseline to a diffuse tumor at PD. BEV, bevacizumab; Plb, placebo.